← Browse by Condition
Medical Condition
colorectal neoplasms
Total Trials
10
Recruiting Now
10
Trial Phases
Phase 4, Phase 2, Phase 1
NCT07158164 Phase 4
Recruiting
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Enrollment
100 pts
Location
United States
Sponsor
Rutgers, The State University ...
NCT06640166 Phase 2
Recruiting
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
Enrollment
25 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
NCT07114601 Phase 1
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Enrollment
421 pts
Location
United States, Canad...
Sponsor
Eli Lilly and Company
NCT02885753 Phase 3
Recruiting
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Enrollment
348 pts
Location
Belgium, France
Sponsor
Federation Francophone de Canc...
NCT06662786 Phase 3
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Enrollment
1,000 pts
Location
United States, Belgi...
Sponsor
Janssen Research & Development...
NCT05239741 Phase 3
Recruiting
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Enrollment
100 pts
Location
China
Sponsor
Merck Sharp & Dohme LLC
NCT05286814 Phase 2
Recruiting
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Enrollment
70 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT06342401
Recruiting
Early Onset Colorectal Cancer Detection
Enrollment
400 pts
Location
United States, Italy...
Sponsor
City of Hope Medical Center
NCT05768178 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT06380816 Phase 1, Phase 2
Recruiting
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Enrollment
167 pts
Location
United Kingdom
Sponsor
Cancer Research UK